This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
Power calculations were conducted to determine a sample size that would detect differences of 5-points on the Clinical Interview Schedule -Revised (CIS-R) psychiatric symptoms scale. A sample of at least 65 patients completing followup in each arm was required to achieve 80% power for the main comparisons at a 5% significance level. Allowing for a 20% dropout rate, a sample of 246 patients was necessary. GPs, during standard consultations, identified eligible patients according to the inclusion and exclusion criteria and referred them by fax. Initially, GPs referred a total of 374 patients of which only 307 met inclusion criteria. Of these, 60 refused to participate in the trial. Thus, 247 patients were included in the study. There was 78 in the GP group, 79 in the CMHN group and 90 in the PST-CMHN group. Fiftythree community nurses were recruited, of which 29 were allocated to the generic nurse care arm and 24 to the nurse PST arm. In total, 98 GPs referred patients for the study.
Study design
This was a randomised, multi-centre (62 GP practices) controlled trial. Initially, nurses were randomly allocated to the generic or problem-solving group. Patient randomisation was conducted through a telephone service provided by the University of York. Stratification was conducted according to GP, with an unstable block size that varied between three and six. Research assistants, masked to patient allocation, conducted the assessments. In addition, patient assessment was self-completed to avoid possible bias.
The patients were followed up at 8 and 26 weeks. Eighty-six per cent were followed up at 8 weeks and 77% at 26 weeks. However, losses to follow-up differed between the three groups. At 8 weeks, 21 (27%) patients were lost to follow-up in the GP group (16 due to refusal and 5 due to intractability), compared with 5 (6.4%) in the CMHN group (3 due to refusal and 2 due to intractability) and 9 (10%) in the PST-CHMN group (7 due to refusal and 2 due to intractability). At 26 weeks, 3 (3.8%) patients were lost to follow-up in the GP group (1 due to refusal and 2 due to intractability), compared with 10 (12.6%) in the CMHN group (2 due to refusal and 8 due to intractability) and 9 (10%) in the PST-CMHN group (4 due to refusal and 5 due to intractability).
Analysis of effectiveness
The analysis of effectiveness was conducted on an intention to treat basis. The primary heath outcome was psychiatric symptoms on the self-completed CIS-R (computerised version PROQSY 3). Scores were compared between the three groups using analysis of covariance. The analysis was conducted separately for the 8-and 26-week assessments. A secondary outcome was social outcome assessed using the self-report Social Adjustment Scale (SAS), a 45-item scale that measures functioning in seven role areas. Patient satisfaction was assessed at 26 weeks using a self-reported questionnaire based on a 5-point scale evaluating the quality of PST. In addition, the degree to which each patient could benefit from CMHN treatment was also assessed using two rapid self-completed questionnaires, the GHQ-12 and Hospital Anxiety and Depression Scale (HADS). It was reported that the patient groups did not differ significantly in terms of their demographic and baseline characteristics. The groups also did not differ significantly in their initial CIS-R generated primary diagnosis, as defined by the International Classification of Diseases (ICD-10).
Effectiveness results
For the CIS-R at 8 weeks, the total mean score was 13.8 (standard deviation, SD=13.9) in the GP group, 16.9 (SD=12.1) in the generic CMHN group and 15.0 (SD=11.4) in the PST-CMHN group. When compared with the GP group, the mean difference in scores was 1.40 (95% confidence interval, CI: -2.79 to 5.6) for the generic CMHN group and -1.21 (95% CI: -5.23 to 2.80) for the PST-CMHN group.
At 26 weeks, the total mean score was 10.1(SD=10.9) in the GP group, 10.4 (SD=9.4) in the generic CMHN group and 12.8 (SD=12.0) in the PST-CMHN group. When compared with the GP group, the mean difference in scores was -1.39 (95% CI: -5.54 to 2.77) for the generic CMHN group and 1.13 (95% CI: -2.88 to 5.14) for the PST-CMHN group. Differences in scores between the groups were not statistically significant.
The patient satisfaction score at 26 weeks was 31.6 (SD=7.6) in the GP group, 37.2 (SD=5.9) in the generic CMHN group and 37.6 (SD=5.8) in the PST-CMHN group. The difference between each of the nurse groups compared with the GP group was statistically significant, (p<0.001).
